Provenzano PP, et al. (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21(3):418-429.
Goel S, et al. (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91(3):1071-1121.
Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8(12):967-975.
Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4(6):437-447.
Collingridge DR, Piepmeier JM, Rockwell S, Knisely JP (1999) Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol 53(2):127-131.
Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38-47.
Tannock IF (1998) Conventional cancer therapy: Promise broken or promise delayed? Lancet 351(Suppl. 2):9-16.
Semenza GL (2011) Oxygen sensing, homeostasis, and disease. N Engl J Med 365(6):537-547.
Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721-732.
Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2(67):e24.
Menon S, et al. (2012) Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal 5(217):ra24.
Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8(11):851-864.
Fan QW, et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9(5):341-349.
Akhavan D, Cloughesy TF, Mischel PS (2010) mTOR signaling in glioblastoma: Lessons learned from bench to bedside. Neuro Oncol 12(8):882-889.
Houghton PJ, et al. (2012) Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer 58(2):191-199.
Majumder PK, et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10(6):594-601.
Kholodenko B, Yaffe MB, Kolch W (2012) Computational approaches for analyzing information flow in biological networks. Sci Signal 5(220):re1.
Wang MY, et al. (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66(16):7864-7869.
Tanaka K, et al. (2011) Oncogenic EGFR signaling activates an mTORC2-NF-?B pathway that promotes chemotherapy resistance. Cancer Discov 1(6):524-538.
Ma C, et al. (2011) A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med 17(6):738-743.
Shi Q, et al. (2012) Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proc Natl Acad Sci USA 109(2):419-424.
Quake SR, Scherer A (2000) From micro-to nanofabrication with soft materials. Science 290(5496):1536-1540.
Apsel B, et al. (2008) Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 4(11):691-699.
Shin YS, et al. (2011) Protein signaling networks from single cell fluctuations and information theory profiling. Biophys J 100(10):2378-2386.
Sarkaria JN, et al. (2006) Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 12(7 Pt 1):2264-2271.
Joo KM, et al. (2013) Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep 3(1):260-273.
Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG (2010) Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 177(3):1491-1502.
Carracedo A, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118(9):3065-3074.
Bailey RC, Kwong GA, Radu CG, Witte ON, Heath JR (2007) DNA-encoded antibody libraries: A unified platform for multiplexed cell sorting and detection of genes and proteins. J Am Chem Soc 129(7):1959-1967.
DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW (2008) Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22(2):239-251.
Horak P, et al. (2010) Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc Natl Acad Sci USA 107(10):4675-4680.
Li Y, et al. (2007) Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb. J Biol Chem 282(49):35803-35813.
Chen H, et al. (2012) mTOR activates hypoxia-inducible factor-1a and inhibits neuronal apoptosis in the developing rat brain during the early phase after hypoxiaischemia. Neurosci Lett 507(2):118-123.
Gibbs JW (1874) On the equilibrium of heterogeneous substances. Trans Conn Acad Arts and Sci 3:343-524.
Alberty RA (1994) Legendre transform in chemical thermodynamics. Chem Rev 94:1457-1482.
Cloughesy TF, et al. (2008) Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5(1):e8.
Chang SM, et al.; North American Brain Tumor Consortium and the National Cancer Institute (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23(4):357-361.
Mellinghoff IK, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353(19):2012-2024.
Shin YS, et al. (2010) Chemistries for patterning robust DNA microbarcodes enable multiplex assays of cytoplasm proteins from single cancer cells. ChemPhysChem 11(14):3063-3069.
